inBiome is an innovative biotechnology company operating on the frontier of infectious disease diagnostics and predictive medicine. The flagship application on inBiome’s proprietary IS-Pro platform is Molecular Culture – the fastest pan-bacterial CE IVD test available. The IS-Pro platform can also be rapidly utilised to meet novel market demands, such as microbiome analysis for non-communicable diseases and patient-outcome prediction diagnostics for high-impact diseases, including COVID-19.

inBiome is headquartered in Amsterdam, the Netherlands.